Direxion Daily S&P Biotech Bear 3X ETF
LABD
17 hedge funds and large institutions have $16.8M invested in Direxion Daily S&P Biotech Bear 3X ETF in 2023 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 6 closing their positions.
169% more call options, than puts
Call options by funds: $11.4M | Put options by funds: $4.21M
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
24% more capital invested
Capital invested by funds: $13.5M → $16.8M (+$3.28M)
0.91% more ownership
Funds ownership: 1.54% → 2.45% (+0.91%)
0% more funds holding
Funds holding: 17 → 17 (0)
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$4.48M |
| 2 |
VF
Virtu Financial
New York
|
+$1.07M |
| 3 |
HF
HRT Financial
New York
|
+$511K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$305K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$158K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2.04M |
| 2 |
JF
Jump Financial
Chicago,
Illinois
|
-$1.26M |
| 3 |
IMC Chicago
Chicago,
Illinois
|
-$1.15M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$556K |
| 5 |
CA
CHI Advisors
New York
|
-$431K |
LABD Hedge Fund Activity: Q1 2023 in Review
17 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Direxion Daily S&P Biotech Bear 3X ETF (LABD) for Q1 2023, worth a combined $16.8M — up 24% from $13.5M a quarter earlier.
Fund positioning in LABD was balanced in Q1 2023: 6 funds opened new positions, 6 closed out, 5 added to existing stakes and 4 trimmed.
The largest buyer was Jane Street, opening a new position worth an estimated $4.48M. The largest seller was Tower Research Capital (TRC), cutting an estimated $2.04M.
- 17 institutional investors held Direxion Daily S&P Biotech Bear 3X ETF (LABD) as of Q1 2023, unchanged from Q4 2022.
- Funds reported $16.8M of Direxion Daily S&P Biotech Bear 3X ETF stock for Q1 2023, up 24% quarter-over-quarter.
- 6 funds opened new Direxion Daily S&P Biotech Bear 3X ETF positions in Q1 2023 and 6 closed out, a net change of 0 holders.
- The largest Direxion Daily S&P Biotech Bear 3X ETF buyer in Q1 2023 was Jane Street, an estimated $4.48M added.
- The largest Direxion Daily S&P Biotech Bear 3X ETF seller in Q1 2023 was Tower Research Capital (TRC), an estimated $2.04M sold.
Based on aggregated 13F filings for Q1 2023.